Aurora-A kinase inhibitors - Pipeline Insight, 2024

This “Aurora-A kinase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aurora-A kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aurora-A kinase inhibitors Understanding

Aurora-A kinase inhibitors: Overview

The Aurora kinases are composed of three highly conserved serine/threonine kinases: Aurora A, B, and C that regulate mitotic and meiotic processes. Aurora-A plays an important role in centrosome maturation, spindle assembly, meiotic maturation, and metaphase I spindle orientation. Aurora A m RNA/protein expression and kinase activity are cell-cycle regulated, with basal level at interphase and expression/activity dramatically increased from late G2 to telophase in mitosis. Aurora A is a mitotic kinase whose depletion primarily leads to mitotic spindle formation defects and consequently prometaphase arrest in human cancer cell lines, evidenced by the increase of histone H3 Ser10 phosphorylation as a mitotic marker. Aurora kinase has emerged as one of the important cell cycle regulator in cancer genesis. Therapeutic inhibition of Aurora kinase showed great promise as probable anticancerregimen.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Aurora-A kinase inhibitors R&D. The therapies under development are focused on novel approaches for Aurora-A kinase inhibitors.

Aurora-A kinase inhibitors Emerging Drugs Chapters

This segment of the Aurora-A kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aurora-A kinase inhibitors Emerging Drugs

LY-3295668: Eli Lilly and Company LY3295668 (AK-01) is a selective, reversible, ATP-competitive small molecule inhibitor of aurora kinase A (AurA). LY3295668 treatment in xenograft and patient-derived xenograft models resulted in tumor growth arrest or regression of several tumor types with an acceptable safety profile. The potential drug is in phase I/II clinical studies in patients with locally advanced or metastatic solidtumors.

TT-00420: Trans Thera Biosciences TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors. TT-00420 in November 2019, received an orphan drug designation from the FDA for the treatmentofcholangiocarcinoma.

Aurora-A kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Aurora-A kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Aurora-A kinase inhibitors

There are approx. 8+ key companies which are developing the Aurora-A kinase inhibitors. The companies which have their Aurora-A kinase inhibitors drug candidates in the most advanced stage, i.e. Phase I/II include, Eli Lilly and Company.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Aurora-A kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aurora-A kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aurora-A kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora-A kinase inhibitors drugs.

Aurora-A kinase inhibitors Report Insights

• Aurora-A kinase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aurora-A kinase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Aurora-A kinase inhibitors drugs?
• How many Aurora-A kinase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Aurora-A kinase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Aurora-A kinase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aurora-A kinase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trans TheraBiosciences
• Eli Lilly and Company
• Takeda Oncology
• Wigen Biomedicine

Key Products

• TT-00420
• LY-3295668
• Alisertib
• WJ-05129